BSE Live
Nov 21, 16:01Prev. Close
927.60
Open Price
930.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 21, 15:59Prev. Close
928.00
Open Price
930.00
Bid Price (Qty.)
924.30 (2)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Zydus Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 14,590.10 | 10,317.60 | 8,421.20 | 7,590.00 | 7,436.70 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 14,590.10 | 10,317.60 | 8,421.20 | 7,590.00 | 7,436.70 | |
| Total Operating Revenues | 15,116.30 | 10,818.70 | 8,731.60 | 7,981.90 | 7,780.00 | |
| Other Income | 696.20 | 1,084.80 | 548.40 | 178.70 | 89.30 | |
| Total Revenue | 15,812.50 | 11,903.50 | 9,280.00 | 8,160.60 | 7,869.30 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 2,787.10 | 3,001.40 | 2,703.50 | 2,629.00 | 2,346.40 | |
| Purchase Of Stock-In Trade | 350.90 | 283.20 | 362.70 | 288.10 | 153.30 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -121.10 | -131.70 | 105.10 | -46.90 | -148.30 | |
| Employee Benefit Expenses | 1,762.20 | 1,507.50 | 1,321.90 | 1,204.90 | 1,147.30 | |
| Finance Costs | 463.90 | 390.70 | 278.20 | 134.90 | 70.90 | |
| Depreciation And Amortisation Expenses | 523.90 | 504.40 | 488.60 | 478.70 | 451.10 | |
| Other Expenses | 2,600.90 | 2,099.60 | 1,784.00 | 1,988.70 | 1,972.60 | |
| Total Expenses | 8,367.80 | 7,655.10 | 7,044.00 | 6,677.40 | 5,993.30 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 7,444.70 | 4,248.40 | 2,236.00 | 1,483.20 | 1,876.00 | |
| Exceptional Items | 0.00 | -8.60 | -203.80 | -319.30 | -187.50 | |
| Profit/Loss Before Tax | 7,444.70 | 4,239.80 | 2,032.20 | 1,163.90 | 1,688.50 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 1,582.50 | 934.30 | 461.80 | 260.20 | 303.30 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 87.30 | -136.00 | 41.20 | 45.80 | -91.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 1,669.80 | 798.30 | 503.00 | 306.00 | 212.30 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 5,774.90 | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 | |
| Profit/Loss From Continuing Operations | 5,774.90 | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 | |
| Profit/Loss For The Period | 5,774.90 | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 57.39 | 34.01 | 15.06 | 8.38 | 14.42 | |
| Diluted EPS (Rs.) | 57.39 | 34.01 | 15.06 | 8.38 | 14.42 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 301.90 | 607.30 | 253.00 | 358.50 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 1,100.00 | 300.00 | 600.00 | 250.00 | 350.00 |
12.11.2025
Zydus Life Standalone September 2025 Net Sales at Rs 2,871.20 crore, up 9.56% Y-o-Y
07.11.2025
Zydus Life Consolidated September 2025 Net Sales at Rs 6,123.20 crore, up 16.92% Y-o-Y
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
24.06.2025
Zydus Life Consolidated March 2025 Net Sales at Rs 6,527.90 crore, up 17.96% Y-o-Y
12.07.2023
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
08.07.2022
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
13.01.2022
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
06.10.2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher